Abstract
Cancers can adapt several evasive functions including apoptosis evasion, self-sufficiency in growth signals, insensitivity to anti-growth signals, sustained angiogenesis, limitless replication potential, tissue invasion and metastasis. The invariable hurdle for development of therapies against such aberrant conditions requires both selective and potent cytotoxicity. Analysis of HIV-1 Vprs apoptotic and anti-proliferative activity have revealed potentially important implications for cancer therapy. Accordingly, we have reviewed the properties of Vpr that will likely contribute to its efficacious function as an anti-tumor agent. Among these are its ability to induce cell cycle arrest, inhibit inflammation, provoke p53 independent apoptosis, and selective killing of rapidly dividing cells.
Keywords: hiv-1, vpr, nf-kappab, p53, mitochondria, cancer, caspase and apoptosis
Current Drug Delivery
Title: HIV-1 Vpr: Enhancing Sensitivity of Tumors to Apoptosis
Volume: 1 Issue: 4
Author(s): Karuppiah Muthumani, Andrew Y. Choo, Daniel S. Hwang, Kenneth E. Ugen and David B. Weiner
Affiliation:
Keywords: hiv-1, vpr, nf-kappab, p53, mitochondria, cancer, caspase and apoptosis
Abstract: Cancers can adapt several evasive functions including apoptosis evasion, self-sufficiency in growth signals, insensitivity to anti-growth signals, sustained angiogenesis, limitless replication potential, tissue invasion and metastasis. The invariable hurdle for development of therapies against such aberrant conditions requires both selective and potent cytotoxicity. Analysis of HIV-1 Vprs apoptotic and anti-proliferative activity have revealed potentially important implications for cancer therapy. Accordingly, we have reviewed the properties of Vpr that will likely contribute to its efficacious function as an anti-tumor agent. Among these are its ability to induce cell cycle arrest, inhibit inflammation, provoke p53 independent apoptosis, and selective killing of rapidly dividing cells.
Export Options
About this article
Cite this article as:
Muthumani Karuppiah, Choo Y. Andrew, Hwang S. Daniel, Ugen E. Kenneth and Weiner B. David, HIV-1 Vpr: Enhancing Sensitivity of Tumors to Apoptosis, Current Drug Delivery 2004; 1 (4) . https://dx.doi.org/10.2174/1567201043334614
DOI https://dx.doi.org/10.2174/1567201043334614 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo
Current Pharmaceutical Design Use of Compound Chinese Medicine in the Treatment of Lung Cancer
Current Drug Discovery Technologies Critical Questions for Preclinical Trials on Safety and Efficacy of Vascular Endothelial Growth Factor-Based Therapeutic Angiogenesis for Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Linear Poly(ethylenimine) Cross-Linked by Methyl-β-Cyclodextrin for Gene Delivery
Current Gene Therapy Gallium-68: A New Trend in PET Radiopharmacy
Current Radiopharmaceuticals Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease
Current Drug Targets Gene Therapy on the Road
Current Gene Therapy Current Status and Perspectives in Ceramide-Targeting Molecular Medicine
Current Pharmaceutical Design Frailty of Older Age: The Role of the Endocrine - Immune Interaction
Current Pharmaceutical Design Approaches Used in Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Melanoma Adjuvant Treatment: Current Insight and Clinical Features
Current Cancer Drug Targets An Overview of Interleukin-1 Receptor Antagonist, Anakinra, in the Treatment of Cutaneous Diseases
Current Clinical Pharmacology Silymarin Extends Lifespan and Reduces Proteotoxicity in C. elegans Alzheimer’s Model
CNS & Neurological Disorders - Drug Targets Molecular Mechanisms and Therapeutic Application of NSAIDs and Derived Compounds in Alzheimers Disease
Current Alzheimer Research Recent Advances and Patents on Nanoscale Systems and Triggerable Drug Delivery in Medical Devices
Recent Patents on Biomedical Engineering (Discontinued) Multimodality Imaging of RNA Interference
Current Medicinal Chemistry Chemometric Evaluation of the Significance of Molecular Structural Descriptors on Binding of Acridinone Derivatives to DNA
Letters in Drug Design & Discovery Aspirin Use on Incidence and Mortality of Gastrointestinal Cancers: Current State of Epidemiological Evidence
Current Pharmaceutical Design Combretastatin A-4 Analogs as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Paris Saponin VII Induces Apoptosis and Cell Cycle Arrest in Erythroleukemia Cells by a Mitochondrial Membrane Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry